阅读说明：本技术 增加四氢生物蝶呤血浆暴露的组合物和方法 (Compositions and methods for increasing tetrahydrobiopterin plasma exposure ) 是由 N·史密斯 J·雷斯 于 2019-05-30 设计创作，主要内容包括：本发明的特点在于包含墨蝶呤或其药学上可接受的盐的组合物,以及用于治疗BH4相关病症的方法。在一些实施方案中,这些组合物和方法导致BH4的血浆暴露的增加。(The invention features compositions comprising sepiapterin or a pharmaceutically acceptable salt thereof, and methods for treating BH 4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma exposure to BH 4.)

1. A method of treating a BH 4-associated disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, with food.

2. A method of increasing BH4 plasma exposure in a subject receiving sepiapterin therapy, comprising administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, with food.

3. A method of reducing the absorption rate of an oral dosage form of sepiapterin or a pharmaceutically acceptable salt thereof, as measured by the concentration of BH4 obtained in plasma over time, in a subject in need thereof, comprising administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, with food.

4. The method of any one of claims 1 to 3, wherein the effective amount is an amount sufficient to produce a concentration of at least 50 ng/mL in the subject's plasma within 10 hours of administration.

5. The method of claim 4, wherein the effective amount comprises a dose at least 20% lower than a dose sufficient to produce a maximum BH4 plasma concentration (Cmax) in the plasma of the subject of at least 50 ng/mL within 10 hours of administration of sepiapterin or a pharmaceutically acceptable salt thereof, without feeding.

6. The method of any one of claims 1 to 5, wherein the effective amount is from 2.5 mg/kg to 100 mg/kg per dose.

7. The method of any one of claims 1 to 6, wherein the administration to the subject occurs less than 30 minutes prior to consumption of food.

8. The method of any one of claims 1 to 7, wherein said administering to said subject is performed substantially simultaneously with eating.

9. The method of any one of claims 1 to 7, wherein the administration is performed immediately after consumption of the food until 2 hours after consumption of the food.

10. The method of any one of claims 1-9, wherein the effective amount results in an increase in the maximum plasma concentration (Cmax) of BH4 as compared to administration without eating.

11. The method of any one of claims 1 to 10, wherein the effective amount results in an area under the concentration time curve from time zero to last concentration of BH4 (AUC) compared to administration without food intake_0-last) And (4) increasing.

12. A pharmaceutical composition comprising sepiapterin or a pharmaceutically acceptable salt thereof, wherein the composition is formulated to increase gastric and/or foregut residence time.

13. The pharmaceutical composition of claim 12, wherein the composition is formulated as a bioadhesive dosage form, a high density dosage form, an expandable dosage form, a superporous hydrogel dosage form, or a floating dosage form.

14. The pharmaceutical composition of claim 13, wherein the buoyant dosage form comprises an ion exchange resin, a buoyant raft system, an inflatable chamber, an effervescent mixture, a swellable hydrocolloid, or a multiparticulate system.

15. A method of treating a BH 4-associated disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 12-14.

16. A method of increasing BH4 plasma exposure in a subject receiving sepiapterin therapy comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 12-14.

17. A method of reducing the absorption rate of an oral dosage form of sepiapterin or a pharmaceutically acceptable salt thereof, as measured by the concentration of BH4 obtained in plasma over time, in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 12-14.

18. The method of claim 1 or 15, wherein the BH 4-associated disorder is BH4 deficiency or phenylketonuria.

19. A method of increasing the level of high vanilloid and/or 5-hydroxyindoleacetic acid in a subject, the method comprising administering an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, with food.

20. The method of claim 19, wherein the level of vanillic acid and/or 5-hydroxyindoleacetic acid in the CSF of the subject is increased.

21. The method of claim 19 or 20, wherein the level of high vanilloid and/or 5-hydroxyindoleacetic acid in the subject is increased by at least 100% compared to the level prior to administration.

Background

Sepiapterin is a naturally occurring precursor of tetrahydrobiopterin (BH4), BH4 is a naturally occurring essential cofactor for key intracellular enzymes including, but not limited to, phenylalanine hydroxylase (PAH) (Kaufman, 1958), Tyrosine Hydroxylase (TH) (Nagatsu et al, 1964), tryptophan hydroxylase (TPH) (Ichiyama et al, 1970), Nitric Oxide Synthase (NOS) (Kwon et al, 1989), (Mayer et al, 1991), and alkylglycerol monooxygenase (AGMO) (Tietz et al, 1964). The rapid conversion of sepiapterin to BH4 occurs via a two-step reduction in the salvage pathway of BH4 synthesis (Sawabe, 2008). Synthetic forms of BH4 (e.g., sapropterin dihydrochloride) are used as therapeutic agents for diseases associated with high plasma phenylalanine levels, such as Phenylketonuria (PKU). PKU is a congenital disorder of metabolism primarily caused by mutations in the PAH gene. BH4 has also been tested as a therapeutic for a variety of central nervous conditions associated with PKU and other diseases, but has shown limited efficacy, presumably due to the inability of BH4 to effectively cross the blood-brain barrier (Klaiman et al, 2013; Grant et al, 2015).

Recent studies have shown that: compared to BH4, peripherally administered sepiapten has greater transmembrane permeability and thus is able to more readily enter liver, kidney, and brain cells. It is reported that: sepiapterin is rapidly converted to BH4 within cells, thereby increasing liver, kidney, and brain BH4 levels (Sawabe, 2008). Thus, sepiapterin is useful as a useful therapeutic agent for diseases associated with low intracellular BH4 levels or dysfunction of various BH 4-dependent metabolic pathways.

Disclosure of Invention

The present invention relates to the following findings: administration of sepiapterin to a subject with food intake unexpectedly results in an increase in BH4 production and an increase in BH4 plasma exposure, CSF exposure, and/or brain exposure of the resulting subject. Without being bound by theory, the increase in BH4 plasma exposure may be caused by a delay in absorption of sepiapterin due to increased gastric residence time or an increase in the absorption rate of sepiapterin due to increased foregut residence timeFrom, or at or slightly above the maximum rate of enzymatic activity (V) of the sepiapterin reductase or dihydrofolate reductase_max) Resulting in a greater percentage of the administered sepiapterin being converted to BH4 prior to passive or active transport into the circulation for excretion and/or elimination. The invention features compositions comprising sepiapterin or a salt thereof, and methods for treating BH 4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma exposure to BH 4.

As is known in the art, food can affect the absorption of compounds. Absorption may be delayed but not reduced, or the total amount of drug absorbed may be reduced. The food effect may be due to a slowing of gastric residence time, a slowing of foregut residence time, a reduction in the arrival of the compound at the site of absorption, a change in the dissolution rate of the compound, or a change in the pH of the stomach. Because of these effects, it is important to establish a specific dosage regimen for drugs that should be administered separately from the meal or under meal.

In one aspect, the invention features a method of treating a BH 4-associated disorder in a subject in need thereof by administering an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, with food.

In another aspect, the invention features a method of increasing BH4 plasma exposure in a subject receiving sepiapterin therapy by administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, with food.

In another aspect, the invention features a method of reducing the absorption rate of an oral dosage form of sepiapterin in a subject in need of therapeutic effect thereof, as measured by the concentration of BH4 obtained in plasma over time. The method comprises administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, with food.

In some embodiments of any of the foregoing methods, the effective amount is an amount sufficient to produce a concentration of BH4 in the plasma of the subject of at least 50 ng/mL (e.g., at least 60 ng/mL, at least 100 ng/mL, at least 200 ng/mL, at least 400 ng/mL, at least 600 ng/mL, at least 1000 ng/mL, or at least 2000 ng/mL) within 10 hours of administration with food (e.g., 2.5 mg/kg to 100 mg/kg per dose). An effective amount can include a dose that is at least 5% (at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, or at least 150%) lower than a dose sufficient to produce a maximum BH4 plasma concentration (Cmax) in the plasma of a subject of at least 50 ng/mL (e.g., at least 60 ng/mL, at least 100 ng/mL, at least 200 ng/mL, at least 400 ng/mL, at least 600 ng/mL, at least 1000 ng/mL, or at least 2000 ng/mL) within 10 hours of administration of sepiapterin without feeding.

In some embodiments of any of the foregoing methods, the administering to the subject occurs less than 30 minutes before consuming the food or after consuming the food (e.g., immediately before until 1 hour after consuming the food). In some embodiments, the administering to the subject is performed substantially simultaneously with the eating. In some embodiments of any of the foregoing methods, the food is a high protein food. In some embodiments of any of the foregoing methods, the food is a high fat food (e.g., at least 25%, 30%, 40%, or 50% of the calories from fat). In some embodiments of any of the foregoing methods, the food is a high protein and high fat food. In some embodiments, the food item is a high calorie food item (e.g., the food item comprises at least 100 calories, e.g., at least 200 calories, at least 300 calories, at least 400 calories, at least 500 calories, e.g., 500-. In some embodiments of any of the foregoing methods, the food is a meal, such as breakfast, lunch, or dinner.

In some embodiments, administration with consumption (e.g., less than 30 minutes before consumption of the food or after consumption of the food, e.g., occurring immediately before consumption of the food until 1 hour after consumption of the food) results in an increase in Cmax of BH4 (e.g., at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, or at least 150%) as compared to administration without consumption (e.g., occurring greater than 2 hours after consumption of the food until 30 minutes before consumption of additional food).

In some embodiments, administration with consumption (e.g., less than 30 minutes prior to consumption of the food or after consumption of the food, e.g., occurring from immediately prior to consumption until 1 hour after consumption of the food) results in a degree of production of BH4 and resulting plasma exposure (AUC) compared to administration without consumption (e.g., less than 30 minutes prior to consumption of the food or after consumption of the food, e.g., occurring from immediately prior to consumption until 1 hour after consumption of the food)_0-last) Increase (e.g., at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, or at least 150%).

In some embodiments of any of the foregoing methods, the sepiapterin is provided in a composition separate from the food consumed (e.g., sepiapterin is not incorporated into a food product). In some embodiments of any preceding aspect, the consuming food occurs prior to administering the sepiapterin (e.g., the consuming food occurs 1 hour prior to administering sepiapterin to immediately prior to administering sepiapterin). In some embodiments, consuming the food occurs after administration of the sepiapterin (e.g., consuming the food occurs immediately after administration to 30 minutes after administration).

In another aspect, the invention features pharmaceutical compositions of sepiapterin or a pharmaceutically acceptable salt thereof, that mimic the effects of administration under fed conditions, e.g., formulated as compositions that increase gastric residence time (e.g., the formulations described in radhakrishhnan et al, Drug Delivery Letters, 2017, 7, 190-200, the formulations of which are incorporated herein by reference).

In some embodiments, the composition is formulated as a bioadhesive dosage form, a high density dosage form, an expandable dosage form, a superporous hydrogel dosage form, or a floating dosage form (e.g., a composition comprising an ion exchange resin, a raft system, inflatable cells, an effervescent mixture, a swellable hydrocolloid, or a multi-particle system).

In another aspect, the invention features a method of treating a BH 4-associated disorder in a subject in need thereof by administering an effective amount of any of the foregoing pharmaceutical compositions.

In yet another aspect, the invention features a method of increasing BH4 plasma exposure in a subject receiving sepiapterin therapy by administering to the subject an effective amount of any of the foregoing pharmaceutical compositions.

In another aspect, the invention features a method of delaying or reducing (e.g., reducing by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%) the absorption rate of oral dosage forms of sepiapterin, as measured by the concentration of BH4 obtained in the plasma of a subject over time, by administering to the subject in need of a therapeutic effect thereof an effective amount of any of the foregoing pharmaceutical compositions.

In one aspect, the invention features a method of increasing the level of high vanilloid and/or 5-hydroxyindoleacetic acid in a subject, the method including administering an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, with food. In some embodiments, the level of vanillic acid and/or 5-hydroxyindoleacetic acid in the cerebrospinal fluid (CSF) of the subject is increased. In some embodiments, the level of homovanillic acid and/or 5-hydroxyindoleacetic acid in the subject (e.g., in the CSF of the subject) is increased by at least 5% compared to the level prior to administration (e.g., the level is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 250%, at least 300% compared to the level prior to administration).

In some embodiments, prior to administration of sepiapten, or a pharmaceutically acceptable salt thereof, the subject has a level of homovanillic acid and/or 5-hydroxyindoleacetic acid that is less than 50% (e.g., less than 40%, less than 30%) of the average subject's level (e.g., the subject has a CSF level of homovanillic acid that is less than 15 ng/mL and/or a CSF level of 5-hydroxyindoleacetic acid that is less than 5 ng/mL). In some embodiments, the subject is not diagnosed as having a BH 4-associated disorder. In some embodiments, the subject is free of symptoms of a BH 4-associated disorder. In some embodiments, the subject has a level of homovanillic acid and/or 5-hydroxyindoleacetic acid that is greater than 50% of the average subject's level (e.g., the subject has a CSF level of homovanillic acid greater than 15 ng/mL and/or a CSF level of 5-hydroxyindoleacetic acid greater than 5 ng/mL) following administration of sepiaptin or a pharmaceutically acceptable salt thereof.

In some embodiments of any of the preceding aspects, the subject has and/or is diagnosed with a BH 4-associated disorder.

In some embodiments of any of the foregoing aspects, the BH 4-associated disorder is primary BH4 deficiency, GTPCH deficiency, 6-pyruvyl-tetrahydropterin synthase (PTPS) deficiency, DHPR deficiency, sepiapterin reductase deficiency, dopamine-responsive dystonia, Segawa syndrome, leucine hydroxylase deficiency, phenylketonuria, DNAJC12 deficiency, parkinson's disease, depression resulting from parkinson's disease, impulse behavior in parkinson's disease, major depression, autism spectrum, ADHD (attention deficit hyperactivity disorder), schizophrenia, bipolar disorder, cerebral ischemia, restless leg syndrome, obsessive compulsive disorder, anxiety, aggression in alzheimer's disease, cerebrovascular disease, subarachnoid post-hemorrhage spasm, inflammation, coronary spasm, cardiac hypertrophy, arteriosclerosis, hypertension, thrombosis, infection, endotoxin shock, stroke, liver cirrhosis, hypertrophic pyloric stenosis, gastric mucosa injury, pulmonary hypertension, renal dysfunction, impotence, or hypoglycemia. In some embodiments of any of the preceding aspects, the BH 4-associated disorder is phenylketonuria, BH4 deficiency (e.g., primary BH4 deficiency), a CNS disorder (e.g., Segawa syndrome, depression, schizophrenia, autism, or parkinson's disease), or a gastrointestinal motility disorder (e.g., gastroparesis and primary and secondary esophageal motility disorders). In some embodiments, the BH 4-associated disorder is BH4 deficiency or phenylketonuria.

Definition of

In this application, unless otherwise clear from the context, (i) the term "a" may be understood to mean "at least one"; (ii) the term "or" may be understood to mean "and/or"; (iii) the terms "comprising" and "comprises" may be understood to encompass a list of elements or steps, whether present individually or in combination with one or more additional elements or steps; and (iv) as will be understood by one of ordinary skill in the art, the terms "about" and "approximately" can be understood to allow for a standard deviation; and (v) when ranges are provided, endpoints are included.

As used herein, the term "administering" refers to administering a composition to a subject. Administration to an animal subject (e.g., to a human) can be by any suitable route. For example, in some embodiments, administration may be bronchial (including by bronchial instillation), buccal, enteral, intradermal, intraepithelial (intradermal), intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal, or intravitreal administration.

The "effective amount" of a compound may vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to induce the desired response. A therapeutically effective amount includes an amount wherein any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. An effective amount also includes an amount sufficient to confer a benefit, e.g., a clinical benefit.

As used herein, the term "food" refers to a solid food having sufficient volume and fat content that it does not dissolve and absorb rapidly in the stomach. For example, meals such as breakfast, lunch or dinner. As used herein, the term "in the context of eating" refers to administration of a composition between about 30 minutes prior to eating (e.g., eating a meal) and about 2 hours after eating. The terms "nonfeeding," "fasting," or "fasting" refer to the condition in which no solid food is consumed for at least about 2 hours to about 30 minutes before additional solid food is consumed.

As used herein, the term "pharmaceutical composition" means a composition containing a compound described herein formulated with a pharmaceutically acceptable excipient. Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., tablets, capsules, caplets, gelcaps, suspensions, solutions, or syrups); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate suppositories and in a solvent system suitable for intravenous use); or in any other pharmaceutically acceptable formulation.

As used herein, the term "pharmaceutically acceptable salt" means any pharmaceutically acceptable salt of sepiapterin. For example, pharmaceutically acceptable salts of sepiapterin include those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: berge et al, J. Pharmaceutical Sciences 66:1-19, 1977 and Pharmaceutical Salts, Properties, Selection, and Use, (P.H.Stahl and C.G.Wermuth eds.), Wiley-VCH, 2008. These salts may be prepared in situ during the final isolation and purification of the compounds described herein, or separately by reacting the free base groups with a suitable organic acid.

Typically, the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids. Suitable pharmaceutically acceptable acids and methods of making suitable salts are well known in the art. Salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.

Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate (benzanesulfonate), benzoate, benzenesulfonate (besylate), bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, gentisate, glucoheptonate, glycerophosphate, glycolate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate (lactobionate), lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, Pectate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, tosylate, undecanoate, and valerate.

As used herein, the term "subject" or "patient" refers to any organism to which a compound or composition according to the invention may be administered, e.g., for experimental, diagnostic, prophylactic and/or therapeutic purposes. Typical subjects include any animal (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans). The subject may seek or require treatment, be receiving treatment, receive treatment in the future, or may be a human or animal that is being cared for by a professional trainer for a particular disease or condition.

As used herein, the term "BH 4-associated disorder" refers to any disease or disorder for which therapeutic benefit may be obtained from modulation of the level or activity of BH 4. BH 4-related disorders include, but are not limited to, primary BH4 deficiency, GTPCH deficiency, 6-pyruvyl-tetrahydropterin synthase (PTPS) deficiency, DHPR deficiency, sepiapterin reductase deficiency, dopamine-responsive dystonia, Segawa syndrome, leucine hydroxylase deficiency, phenylketonuria, DNAJC12 deficiency, Parkinson's disease-induced depression, Parkinson's disease-induced impulsivity, major depression, autism spectrum, ADHD, schizophrenia, bipolar disorder, cerebral ischemia, restless leg syndrome, obsessive-compulsive disorders, anxiety disorders, aggression in Alzheimer's disease, cerebrovascular disease, subarachnoid post-hemorrhage spasm, myocarditis, coronary spasm, cardiac hypertrophy, arteriosclerosis, hypertension, thrombosis, infection, endotoxin shock, liver cirrhosis, hypertrophic pyloric stenosis, gastric mucosal injury, gastric ulcer, and combinations thereof, Pulmonary hypertension, renal dysfunction, impotence, or hypoglycemia. In some embodiments of any of the preceding aspects, the BH 4-associated disorder is phenylketonuria, BH4 deficiency (e.g., primary BH4 deficiency), a CNS disorder (e.g., Segawa syndrome, depression, schizophrenia, autism, or parkinson's disease), or a gastrointestinal motility disorder (e.g., gastroparesis and primary and secondary esophageal motility disorders). In some embodiments, the BH 4-associated disorder is BH4 deficiency or phenylketonuria.

As used herein, the term "treatment" or "treating" means both therapeutic treatment and prophylactic (preventative) measures, wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder or disease, or to obtain a beneficial or desired clinical result. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; a reduction in the extent of the condition, disorder or disease; a stable (i.e., not worsening) state of the condition, disorder or disease; a delay in onset or slowing of progression of the condition, disorder or disease; amelioration or palliation (whether partial or total), whether detectable or undetectable, of a condition, disorder, or disease state; an improvement in at least one measurable physical parameter, not necessarily discernible by the patient; or a gain or amelioration of the condition, disorder or disease. Treatment includes induction of clinically significant responses without excessive levels of side effects. Treatment also includes extended survival compared to expected survival in the absence of treatment.

Drawings

Figure 1 is a graph illustrating the mean plasma concentration of BH4 over time in fed and fasted subjects.

Fig. 2 is a graph illustrating mean plasma concentrations of sepiapterin over time in fed and fasted subjects.

Detailed Description

The present inventors have discovered that administration of sepiapterin or a pharmaceutically acceptable salt thereof with food unexpectedly results in an increase in BH4 plasma exposure in a subject. Accordingly, the invention features compositions comprising sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for treating BH 4-related disorders. These compositions and methods can result in an increase in plasma exposure to BH 4.

Sepiapterin

The sepiapterin enters the cell and is converted to 7, 8-dihydrobiopterin by sepiapterin reductase. 7, 8-dihydrobiopterin is then converted to BH4 via reduction by dihydrofolate reductase.

Without being bound by theory, administration of sepiapterin with food, for example, results in an increase in plasma exposure of BH4 by decreasing the rate of absorption of sepiapterin. If the administered sepiapterin is rapidly absorbed, e.g., by fasting administration, the sepiapterin reductase and/or dihydrofolate reductase in the cell can be above V_maxBecomes saturated, resulting in at least a portion of the administered sepiapterin leaving the cell without being reduced to 7, 8-dihydrobiopterin and subsequently to BH 4. This excess of sepiapterin can then be excreted without ever being converted to BH4, resulting in lower levels of BH4 in the plasma than when sepiapterin is administered with meal, which reduces the rate of absorption of sepiapterin or prolongs the absorption of sepiapterin, and results in a reaction rate that is lower than, at, or slightly higher than the substrate saturation V of sepiapterin reductase and/or dihydrofolate reductase_max. Administration of sepiapterin with food unexpectedly resulted in an increase in the maximum BH4 plasma concentration (Cmax) and exposure by the area under the concentration time curve from zero time to the final concentration of BH4 (AUC) as compared to administration without food_0-last) And (6) measuring.

Sepiapterin has the following structure:

sepiapterin.

Sepiapterin or a pharmaceutically acceptable salt thereof can be formulated into a pharmaceutical composition. In some embodiments, the pharmaceutical compositions of the present invention comprise 20-30%, such as 20%, 22%, 25%, 27%, or 30% by total weight of sepiapterin or a salt thereof. In some embodiments, the pharmaceutical composition comprises greater than 20%, such as greater than 25%, greater than 30%, greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%, or greater than 90% by total weight of sepiapterin. In some embodiments, the pharmaceutical composition comprises less than 20%, such as less than 20%, less than 15%, less than 10%, or less than 5% by total weight of sepiapterin.

In some embodiments, the invention features a pharmaceutical composition that includes sepiapterin or a salt thereof, and less than 10%, e.g., 9%, 7%, 5%, 3%, 1%, 0.5%, 0.25%, or 0.1% antioxidant by total weight. The antioxidant may be ascorbic acid. In some embodiments, the ratio of sepiapterin or a pharmaceutically acceptable salt thereof to antioxidant is 1:1, e.g., 2:1, 5:1, 7:1, or 10: 1. The pharmaceutical composition may comprise 20-30%, such as 20%, 22%, 25%, 27% or 30% by total weight of sepiapterin or a pharmaceutically acceptable salt thereof. The pharmaceutical composition may also contain a dispersing agent, such as croscarmellose sodium. The pharmaceutical composition may comprise 0.1-1.5%, for example 0.1%, 0.5%, 1% or 1.5% by total weight of dispersing agent. In some embodiments, the pharmaceutical composition comprises at least one anti-caking agent, such as colloidal silicon dioxide or microcrystalline cellulose. The pharmaceutical composition may comprise 65-75% by total weight, for example 65%, 67%, 70%, 73% or 75% of an anti-caking agent. In some embodiments, the pharmaceutical composition comprises both colloidal silicon dioxide and microcrystalline cellulose. In some embodiments, the pharmaceutical composition comprises 60-65% by total weight of microcrystalline cellulose and 5-7% by total weight of colloidal silicon dioxide. In some embodiments, the crystalline form of sepiapterin is formulated as particles having a particle size of less than 140 μm, e.g., 120 μm, 110 μm, 100 μm, 90 μm, 80 μm, 70 μm, 60 μm, 50 μm, 40 μm, 30 μm, 20 μm, 10 μm, or 5 μm. In some embodiments, the pharmaceutical composition comprises less than 1% of an impurity, such as lactopterin (lactosylpterin), for example, the composition comprises less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, or less than 0.2% of an impurity.

In some embodiments, the sepiapterin is a salt of sepiapterin, such as a salt with sulfuric acid, p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid, malonic acid, tartaric acid (e.g., L-tartaric acid), phosphoric acid, gentisic acid, fumaric acid, glycolic acid, acetic acid, or nicotinic acid.

In some embodiments, the sepiapterin or a pharmaceutically acceptable salt thereof is in a crystalline form. The crystalline form of crystalline sepiapterin free base or sepiapterin salt may exist as an anhydrate (e.g., without any bound water or solvent or hydration or solvation) or as a hydrate, partial hydrate (e.g., hemihydrate, sesquihydrate, etc.), as a dihydrate, trihydrate, or the like, wherein the crystalline form binds to the hydrated water or solvent molecules associated with the crystalline form of sepiapterin or sepiolierin salt. In one embodiment, crystalline sepiapterin is present in the form of a monohydrate or a hemihydrate.

In some embodiments, the sepiapterin is present in crystalline form. In some embodiments, the crystalline form of sepiapterin is characterized by an X-ray powder diffraction pattern obtained by irradiation with Cu ka X-rays having at least peaks expressed in 2 Θ at about 9.7 °, about 10.2 °, and about 11.3 °. In other embodiments, the crystalline form of sepiapterin is characterized by an X-ray powder diffraction pattern obtained by irradiation with Cu ka X-rays having at least peaks, expressed in terms of 2 Θ, at about 9.7 °, about 10.2 °, about 11.3 °, about 14.0 °, about 14.6 °, about 19.9 °, about 22.2 °, about 25.3 °, and about 32.4 °.

The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof.

The pharmaceutically acceptable excipient may be any conventionally used excipient and is limited only by chemical-physical considerations (such as solubility) and by the route of administration. One skilled in the art will appreciate that in addition to the pharmaceutical compositions described below, the sepiapterin may be formulated as an inclusion complex, such as a cyclodextrin inclusion complex, or a liposome.

The pharmaceutically acceptable excipients (e.g., vehicles, adjuvants, excipients, or diluents) described herein are well known to those skilled in the art and readily available to the public. Preferably, the pharmaceutically acceptable excipient is an excipient that is chemically inert to sepiapterin and is an excipient that does not have deleterious side effects or toxicity under the conditions of use.

Preparation for increasing gastric and/or foregut residence time

Gastric resident drug delivery is a method by which a drug formulation is designed to remain in the stomach for a longer period of time (e.g., until drug release is complete).

Bioadhesive dosage forms utilize polymers that are capable of adhering to surfaces and resulting in controlled release of the drug. The bioadhesive polymer may be anionic (e.g., carboxymethylcellulose, alginic acid, polyacrylic acid, pectin, carrageenan, polycarbophil, or carbomer); cationic (e.g., chitosan, polylysine, or polybrene); or non-ionic (e.g., polyethylene glycol, polyvinylpyrrolidone, dextran, or hydroxypropyl methylcellulose).

The high density dosage form is designed to be located in the stomach at a level below the pyloric sphincter, thereby avoiding emptying. Excipients suitable for high density dosage forms include iron powder, barium sulfate, zinc oxide, and titanium oxide.

The expandable dosage form is designed to expand in the stomach to greater than the pyloric sphincter, thereby avoiding emptying. For example, a dosage form comprising a drug core, a swellable hydrocolloid, and an outer semipermeable polymer is suitable for an expandable dosage form.

Like the swellable dosage forms, the superporous hydrogel dosage forms are designed to swell in the stomach above the pyloric sphincter. The superporous hydrogel dosage form may contain a polymer, such as croscarmellose sodium.

Floating dosage forms are designed to have a lower density than gastric juice. The buoyant dosage form may comprise a composition comprising an ion exchange resin, a buoyant raft system, an inflatable chamber, an effervescent mixture, a swellable hydrocolloid, or a multiparticulate system.

Antioxidant agent

Sepiapterin readily oxidizes rapidly when exposed to air. Accordingly, the pharmaceutical composition of the present invention may comprise an antioxidant. The antioxidant can minimize oxidative degradation of sepiapterin. Examples of antioxidants include, but are not limited to, ascorbic acid, tocopherol, retinol, ascorbyl palmitate, N-acetyl cysteine, glutathione, ethylene diamine tetraacetic acid, sodium bisulfite, sodium metabisulfite, thiourea, butylated hydroxytoluene, butylated hydroxyanisole, and vitamin E. In some embodiments, the pharmaceutical compositions of the invention comprise ascorbic acid, tocopherol, retinol, ascorbyl palmitate, N-acetyl cysteine, glutathione, butylated hydroxytoluene and/or butylated hydroxyanisole as an antioxidant.

In some embodiments, the pharmaceutical composition comprises less than 10%, e.g., less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, or is substantially free of antioxidant by weight. In some embodiments, the pharmaceutical composition comprises 2-9%, e.g., 2-4%, 3-5%, 4-6%, 5-7%, 6-8%, or 7-9% antioxidant by total weight. In some embodiments, the pharmaceutical composition comprises 5-100% of the maximum daily dosage of USP of antioxidant, e.g., in some embodiments, the pharmaceutical composition comprises 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the maximum daily dosage of USP of antioxidant. In some embodiments, the ratio of sepiapterin to antioxidant is at least 1:1, such as 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or 10: 1.

Dispersing agent

In some embodiments, the pharmaceutical composition of the invention comprises at least one dispersing agent. The dispersing agent may cause the particles in the formulation to separate, for example, releasing their drug substance upon contact with moisture. Examples of dispersing agents include, but are not limited to, crospovidone, carboxymethylcellulose (e.g., a cross-linked carboxymethylcellulose salt, such as cross-linked sodium carboxymethylcellulose), starch (e.g., sodium starch glycolate), or alginic acid. In some embodiments, the dispersing agent in the pharmaceutical composition is a carboxymethyl cellulose, such as a pharmaceutically acceptable salt of a cross-linked carboxymethyl cellulose. In some embodiments, the pharmaceutical composition may comprise 0.1-1.5%, such as 0.1%, 0.5%, 1%, or 1.5% by total weight of the dispersing agent. In some embodiments, the pharmaceutical composition comprises less than 1.5%, such as less than 1%, less than 0.5%, or less than 0.1% of a dispersing agent.

Anti-caking agent

In some embodiments, the pharmaceutical compositions of the present invention comprise at least one anti-caking agent. In some embodiments, the pharmaceutical composition comprises at least two anti-caking agents. Exemplary anticaking agents include colloidal silicon dioxide, microcrystalline cellulose, tricalcium phosphate, microcrystalline cellulose, magnesium stearate, sodium bicarbonate, sodium ferrocyanide, potassium ferrocyanide, calcium phosphate, sodium silicate, colloidal silicon dioxide, calcium silicate, magnesium trisilicate, talc, sodium aluminosilicate, potassium aluminum silicate, calcium aluminosilicate, bentonite, aluminum silicate, stearic acid, and polydimethylsiloxane. In some embodiments, the at least one anti-caking agent is colloidal silicon dioxide or microcrystalline cellulose. In some embodiments, the pharmaceutical composition may comprise 65-75%, e.g., 65%, 67%, 70%, 73%, or 75% by total weight of the anti-caking agent. In some embodiments, the pharmaceutical composition comprises both colloidal silicon dioxide and microcrystalline cellulose. In some embodiments, the pharmaceutical composition comprises 60-65% by total weight of microcrystalline cellulose and 5-7% by total weight of colloidal silicon dioxide.

Administration vehicle

In some embodiments, a pharmaceutical composition of the invention is combined with a dosing vehicle prior to administration, for example, a dosing vehicle having a viscosity of about 50-1750 centipoise (cP). One type of suspending agent that may be used is a combination of glycerol and sucrose in water (e.g., MEDISCA @oralblends containing 2.5% glycerol and 27% sucrose in water). An appropriate amount of the composition can be added to the dosing vehicle mixture just prior to administration and stirred to suspend the composition.

Other suspending agents may also be used as administration vehicles. Exemplary suspending agents include agar, alginic acid, sodium carboxymethylcellulose, carrageenan, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, methyl cellulose, polyethylene glycol, povidone, tragacanth, xanthan gum, or other suspending agents known in the art.

Dosage form

Sepiapterin or a pharmaceutically acceptable salt thereof can be used in any suitable dosage. Suitable dosages and dosage regimens can be determined by conventional range determination techniques. Typically, treatment is initiated with smaller doses than the optimal dose. Thereafter, the dosage is increased in small increments until the best effect under such circumstances is achieved. For convenience, the total daily dose may be divided and administered in portions throughout the day, if desired. The present invention provides a wide range of responses at appropriate dosages and when certain compounds are administered appropriately. Typically, the dosage ranges from about 2.5 to about 150 mg/kg of patient body weight being treated per day. For example, in embodiments, sepiapterin or a pharmaceutically acceptable salt thereof, may be administered once or more times per day at about 20 mg/kg to about 150 mg/kg, about 40 mg/kg to about 100 mg/kg, about 100 mg/kg to about 150 mg/kg, about 60 mg/kg to about 120 mg/kg, about 80 mg/kg to about 100 mg/kg, about 40 mg/kg to about 60 mg/kg, about 2.5 mg/kg to about 20 mg/kg, about 2.5 mg/kg to about 10 mg/kg, or about 2.5 mg/kg to about 5 mg/kg of the subject's body weight per day to achieve the desired therapeutic effect.

In some embodiments, the dose is an amount sufficient to produce BH4 levels in the CNS (e.g., brain) (e.g., as measured in CSF) and/or sufficient to produce a therapeutic outcome and/or response (e.g., an increase in serotonin or dopamine levels in the CNS). In some embodiments, an increase in BH4 in the CNS is measured by determining the level of a monoamine metabolite, such as serotonin and/or dopamine (e.g., homovanillic acid or 5-hydroxyindoleacetic acid (5-HIAA)) in the CSF, wherein an increase in the metabolite in the CSF is indicative of an increase in BH4 levels in the CNS (e.g., brain). In some embodiments, the dose is an amount sufficient to increase a level of BH4 to at least two-fold (e.g., at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, or at least 150-fold) as compared to a level of BH4 prior to administration, the level of BH4 being measured in a plasma or organ of a subject (e.g., a liver of a subject).

In some embodiments, the sepiapterin or a pharmaceutically acceptable salt thereof may be formulated in a unit solid oral dosage form, e.g., a granule. In these embodiments, each unit solid oral dosage form may comprise any suitable amount of sepiapterin or a pharmaceutically acceptable salt thereof. For example, each solid oral dosage form may comprise about 2.5 mg, about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg.

Sepiapterin or a pharmaceutically acceptable salt thereof may be used to prepare liquid formulations, for example in the form of solutions, suspensions or emulsions. Formulations suitable for oral administration may include: (a) capsules, sachets, tablets, lozenges and troches, each containing a predetermined amount of the active ingredient as a solid or granules; (b) powder; (c) liquid solutions, such as an effective amount of the compound dissolved in a diluent (e.g., water, saline, or orange juice); (d) a suspension in a suitable liquid; and (e) a suitable emulsion. Solid oral dosage forms, such as capsule forms, tablet forms and powder forms are preferred. The capsule form may be that of a conventional hard or soft shell gelatin type containing, for example, surfactants, lubricants and inert fillers such as lactose, sucrose, calcium phosphate and corn starch. Tablet forms may include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, wetting agents, preservatives, flavoring agents, and pharmacologically compatible excipients. Lozenge forms may comprise the active ingredient in a flavoring agent, typically sucrose and acacia or tragacanth, as well as lozenges, emulsions, gels, etc., comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, which in addition to the active ingredient comprise those excipients known in the art.

Formulations suitable for oral and/or parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions (which may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient) and aqueous and non-aqueous sterile suspensions (which may contain suspending agents, solubilizers, thickeners, stabilizers, and preservatives). The compounds may be administered in physiologically acceptable diluents, such as sterile liquids or liquid mixtures, in pharmaceutical excipients, including water, saline, aqueous dextrose and related sugar solutions, alcohols such as ethanol, benzyl or cetyl alcohol, glycols such as propylene or polyethylene glycol and other polyvinyl alcohols, glycerol ketals such as 2, 2-dimethyl-1, 3-dioxolane-4-methanol, ethers such as poly (ethylene glycol) 400, oils, fatty acids, fatty acid esters or glycerides, or acetylated fatty acid glycerides, with or without the addition of pharmaceutically acceptable surfactants such as soaps or detergents, suspending agents such as pectin, carbomers, methyl cellulose, hydroxypropyl methyl cellulose or carboxymethyl cellulose, or emulsifiers and other pharmaceutical adjuvants.

The invention features an orally-tolerated pharmaceutical composition of a formulation that contains a therapeutically effective amount of sepiapterin and less than 10% antioxidant. In some embodiments, the pharmaceutical composition is a granular formulation dispersed in a pharmaceutically acceptable excipient, e.g., the composition can be mixed into water and ingested by the patient (e.g., over the course of 5 to 10 minutes). Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, philiadelphia, PA, 22 nd edition, 2010. Any conventional excipient is contemplated for use in pharmaceutical compositions unless incompatible with the active ingredient. Furthermore, for animal (e.g., human) administration, it is understood that the formulation should meet sterility, pyrogenicity, general safety and purity standards as required by the FDA office of biological standards.

Oils that may be used in parenteral formulations include petroleum, animal, vegetable or synthetic oils. Specific examples of oils include peanut oil, soybean oil, sesame oil, cottonseed oil, corn oil, olive oil, petrolatum, and mineral oil. Suitable fatty acids for parenteral formulation include oleic acid, stearic acid and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters. Suitable soaps for parenteral formulations include fatty alkali metal, ammonium and triethanolamine salts, and suitable detergents include (a) cationic detergents such as dimethyl dialkyl ammonium halides and alkyl pyridinium halides, (b) anionic detergents such as alkyl, aryl and olefin sulfonates, alkyl, olefin, ether and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as fatty amine oxides, fatty acid alkanolamides and polyoxyethylene-polypropylene copolymers, (d) amphoteric detergents such as alkyl- β -aminopropionates and 2-alkyl-imidazopeak quaternary ammonium salts, and mixtures thereof.

Parenteral formulations typically contain about 20% to about 30% by weight of sepiapterin or a pharmaceutically acceptable salt thereof in solution. Suitable preservatives and buffers may be employed in such formulations. To minimize or eliminate irritation at the injection site, such compositions may contain one or more nonionic surfactants having a hydrophilic-lipophilic balance (HLB) of from about 12 to about 17. The amount of surfactant in such formulations is from about 5% to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. Parenteral formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid excipient for injection, for example water, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, tablets of the kind previously described.

The sepiapterin or a pharmaceutically acceptable salt thereof of the present invention can be prepared into an injectable formulation. The requirement for effective pharmaceutical excipients for injectable compositions is well known to those of ordinary skill in the art. See alsoRemington: The Science and Practice of Pharmacy22 nd edition, Lippincott Williams&Wilkins, (2012); andEncyclopedia of Pharmaceutical Technologyj, Swarbrick and j.c. Boylan eds 2006 Marcel Dekker, new york, each of which is incorporated herein by reference.

Topical formulations, including those useful for transdermal drug delivery, are well known to those skilled in the art and are suitable for application to the skin in the context of the present invention. Compositions for topical application are typically in the form of liquids, creams, pastes, lotions and gels. Topical administration includes application to the oral mucosa, which includes the oral cavity, oral epithelium, palate, gums, and nasal mucosa. In some embodiments, the composition comprises sepiapterin or a pharmaceutically acceptable salt thereof, and a suitable vehicle or excipient. It may also contain other components, such as anti-irritants. The excipient may be liquid, solid or semi-solid. In embodiments, the composition is an aqueous solution. Alternatively, the composition may be a dispersion, emulsion, gel, lotion or cream vehicle for the various components. In one embodiment, the primary vehicle is water or a biocompatible solvent that is or has become substantially neutral. The liquid vehicle may include other materials, such as buffers, alcohols, glycerin, and mineral oil, as well as various emulsifying or dispersing agents known in the art to achieve the desired pH, consistency, and viscosity. The composition may be made into a solid, such as a powder or granules. The solid may be applied directly, or dissolved in water or a biocompatible solvent to form a substantially neutral solution or a solution that has become substantially neutral prior to use, which may then be applied to the target site. In embodiments of the present invention, vehicles for topical application to the skin may include water, buffer solutions, various alcohols, glycols such as glycerin, lipid materials such as fatty acids, mineral oils, phosphoglycerides, collagen, gelatin, and silicone-based materials.

Sepiapterin or a salt thereof (alone or in combination with other suitable components) can be formulated as an aerosol formulation for administration by inhalation. These aerosol formulations may be placed in a pressurized acceptable propellant such as dichlorodifluoromethane, propane, nitrogen, and the like. They may also be formulated as medicaments for non-pressurized formulations, for example in a nebulizer or atomizer.

In addition, sepiapterin or a pharmaceutically acceptable salt thereof may be prepared into suppositories by mixing with various bases such as an emulsifying base or a water-soluble base. Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such excipients as are known in the art to be suitable.

Solid dosage form for oral administration

Formulations for oral use include granules containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients, and such formulations are known to those skilled in the art (e.g., U.S. Pat. Nos. 5,817,307, 5,824,300, 5,830,456, 5,846,526, 5,882,640, 5,910,304, 6,036,949, 6,372,218, which are incorporated herein by reference). Excipients may be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starch (including potato starch), calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate, or sodium phosphate); granulating and disintegrating agents (e.g., cellulose derivatives, including microcrystalline cellulose, starches, including potato starch, croscarmellose sodium, alginates, or alginic acid); a binder (e.g., sucrose, glucose, sorbitol, acacia, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, polyvinylpyrrolidone, or polyethylene glycol); and lubricants, glidants, antiadherents (e.g., magnesium stearate, zinc stearate, stearic acid, silicon dioxide, hydrogenated vegetable oils or talc) and anticaking agents (e.g., colloidal silicon dioxide, microcrystalline cellulose, tricalcium phosphate, microcrystalline cellulose, magnesium stearate, sodium bicarbonate, sodium ferrocyanide, potassium ferrocyanide, calcium phosphate, sodium silicate, colloidal silicon dioxide, calcium silicate, magnesium trisilicate, talc, sodium aluminosilicate, potassium aluminosilicate, calcium aluminosilicate, bentonite, aluminum silicate, stearic acid, polydimethylsiloxane). Other pharmaceutically acceptable excipients may be colorants, flavors, plasticizers, humectants and buffers. In some embodiments, an excipient (e.g., a flavoring agent) is packaged with the composition. In some embodiments, the excipient (e.g., flavoring agent) is packaged separately from the composition (e.g., combined with the composition prior to administration).

The solid compositions of the present invention may include a coating suitable for protecting the composition from undesired chemical changes (e.g., chemical degradation prior to release of the active). May be similar to that of the aboveEncyclopedia of Pharmaceutical TechnologyThe coatings are applied to the solid dosage forms in a similar manner as described in (1).

Powders and granules may be prepared in a conventional manner using the above-mentioned ingredients using, for example, mixers, fluid bed equipment, melt solidification equipment, rotor granulators, extrusion/spheronization machines or spray drying equipment.

Method of treatment

Sepiapterin is useful as a useful therapeutic agent for conditions associated with low levels of intracellular BH4 or with dysfunction of multiple BH 4-dependent metabolic pathways, including, but not limited to, primary BH4 deficiency, GTPCH deficiency, 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency, DHPR deficiency, sepiapterin reductase deficiency, dopamine-responsive dystonia, Segawa syndrome, tyrosine hydroxylase deficiency, phenylketonuria, DNAJC12 deficiency, parkinson's disease-induced depression, impulse behavior in parkinson's disease, major depression, autism spectrum, ADHD, schizophrenia, bipolar disorder, cerebral ischemia, restless leg syndrome, obsessive compulsive disorder, anxiety, aggression in alzheimer's disease, cerebrovascular disease, subarachnoid hemorrhage post spasm, myocarditis, coronary vasospasm, cardiac hypertrophy, or a combination thereof, Arteriosclerosis, hypertension, thrombosis, infection, endotoxic shock, liver cirrhosis, hypertrophic pyloric stenosis, gastric mucosa injury, pulmonary hypertension, renal dysfunction, sexual impotence, and hypoglycemia. Thus, various forms of sepiapterin or salts thereof according to the present invention may be administered to a patient in an effective amount to achieve treatment or amelioration of a disease, disorder, or condition.

In some embodiments of any of the foregoing methods, the food is a high protein food. In some embodiments of any of the foregoing methods, the food is a high fat food (e.g., at least 25%, 30%, 40%, or 50% of the calories from fat). In some embodiments of any of the foregoing methods, the food is a high protein and high fat food. In some embodiments, the food item is a high calorie food item (e.g., the food item comprises at least 100 calories, e.g., at least 200 calories, at least 300 calories, at least 400 calories, at least 500 calories, e.g., 500-. In some embodiments of any of the foregoing methods, the food is a meal, such as breakfast, lunch, or dinner.

The actual dosage of the compositions of the invention to be administered to a patient may be determined by physical and physiological factors (e.g., body weight, severity of the condition, type of disease being treated, previous or concurrent therapeutic intervention, specific disease of the patient) and the route of administration. Depending on the dose and route of administration, the preferred dose and/or the number of administrations of the effective amount may vary depending on the subject's response. In any event, the practitioner responsible for administration will determine the concentration of the active ingredient in the composition and the appropriate dosage for the individual subject.

In some embodiments, the patient receives 2.5 mg/kg/day, 5 mg/kg/day, 10 mg/kg/day, 20 mg/kg/day, 40 mg/kg/day, 60 mg/kg/day, or 80 mg/kg/day. During the treatment period, the patient may receive the pharmaceutical composition comprising sepiapterin once a day, twice a day, or three times a day during the treatment period. In some embodiments, in addition to replenishing BH4 (if the patient is taking BH4), the patient continues with other drugs that they are currently using for BH 4-related disorders (e.g., prescribed L-dopa/carbidopa, 5HTP, melatonin, MAO inhibitors, and dopamine receptor agonists). The patient may not be allowed to take any drug known to inhibit folate synthesis (e.g., methotrexate, pemetrexed, or trimetrexate).

In some embodiments, a patient taking BH4 discontinues administration of BH4 (i.e., BH4 elution). Blood samples for Phe concentration may be obtained during BH4 elution at 7, 5, 3, and 1 days prior to treatment with the pharmaceutical composition of the invention or up to any time point during BH4 elution when blood Phe levels > 360 μmol/L. In some embodiments, a blood sample is tested for sepiapterin, Phe, BH4, and tyrosine (Tyr) prior to administration.

Equivalents and ranges

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the invention is not intended to be limited by the above description but rather is as set forth in the following claims.

Furthermore, it should be understood that any particular embodiment of the invention falling within the scope of the prior art may be explicitly excluded from any one or more claims. Since such embodiments are considered to be known to those of ordinary skill in the art, they may be excluded even if the exclusion is not explicitly set forth herein. Any particular embodiment of the compositions of the present invention (e.g., any compound; any method of manufacture; any method of use; etc.) can be excluded from any one or more claims for any reason, whether or not related to the presence of prior art.

Examples

Example 1 evaluation of the Effect of food on the administration of sepiapterin

The method comprises the following steps: subjects received 2 oral doses of sepiapterin (10 mg/kg) in the fasted and fed states at 1 week intervals. Starting 30 minutes before receiving its second oral dose of sepiapterin on day 8, subjects were fed a standard high fat (approximately 50% of the total calories of the diet) and high calorie (approximately 800 to 1000 calories) diet.

Sampling for PK analysis occurred before dosing on days 1 and 8 (within 30 minutes before dosing) and 0.5, 1, 2, 4, 8, 12 and 24 hours after dosing on days 1 and 8. Blood concentrations of sepiapterin and BH4 were analyzed by MNG Labs.

Cerebrospinal fluid (CSF) was collected from selected subjects by lumbar puncture approximately 30 minutes from the time of maximum observed plasma BH4 concentration (Tmax) as determined from blood analysis on day 1 (before dosing) and day 7 (i.e., 7 days after daily dosing).

Cerebrospinal fluid (CSF) was analyzed by MNG Labs. Descriptive statistics are provided to characterize any change in neurotransmitter metabolism between the day 1 sample results and the day 7 sample results.

As a result: as shown in tables 1 and 2 below, and in figure 1, surprisingly, Cmax of BH4 in the plasma of subjects with food prior to administration was much higher compared to subjects who fasted prior to administration. Furthermore, when sepiapterin was administered in the fed state, plasma sepiapterin concentrations decreased, but BH4 concentrations increased, relative to sepiapterin administered in the fasted state (fig. 1). Geometric mean ratio of plasma sepiapterin (fasted/fed, 90% CI) versus AUC_lastIs 1.29 (0.84 to 2.00), and for C_maxIt was 1.57 (1.21 to 2.0). Corresponding ratio of plasma BH4 (90% CI) versus AUC_0–inf0.58 (0.47 to 0.71), and for C_max0.55 (0.45 to 0.68). When administered in the fed state, as compared to administration of sepiapten in the fasted state, e.g., by AUC₀-_infAnd AUC_lastThe total exposure of BH4 measured increased by a factor of 1.7.

TABLE 1 summary of BH4 concentrations in plasma of fasted subjects

TABLE 2 summary of BH4 concentrations in plasma of fed subjects

In addition, as shown in table 3, table 4, and figure 2 below, surprisingly, Cmax of sepiapterin in the subject's plasma was much lower when fed prior to administration compared to subjects fasted prior to administration.

TABLE 3 summary of the concentration of sepiapterin in plasma of fasted subjects

TABLE 4 summary of the concentration of sepiapterin in the plasma of fed subjects

Example 2 comparison of adverse events in fed and fasted subjects

The method comprises the following steps: twelve subjects were given a single dose (10 mg/kg) of sepiapterin under fasting conditions, and then 7 days later were administered under fed conditions. Standard definition of Adverse Events (AE) was used. All-cause AEs are those that occur at any time; treatment-emergent adverse events (TEAEs) were those that occurred at or after the time of administration of the study treatment. TEAE related to study drug was based on the investigator's opinion. A severe AE is defined as a life-threatening or leading to death, hospitalization, or extension of an existing hospitalization, or a substantial disruption of sustained or significant disability/inability or the ability to carry out normal vital functions, or a congenital abnormality/birth defect.

As a result: as shown in table 5, surprisingly, when sepiapterin is administered to fed subjects, the incidence of adverse events is reduced compared to fasted subjects.

TABLE 5 comparison of adverse events under fasting and fed conditions

Example 3 measurement of CSF levels of neurotransmitters after administration of sepiapterin

The method comprises the following steps: CSF samples of subjects administered 60 mg/kg sepiapterin or placebo were analyzed. The following analytes were measured: sepiapterin, BH4, BH2, homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (HIAA). For each analyte, the analytes were determined from T on days 1 and 7_maxDescriptive of +/-30 minutes (n, mean, SD, median, A,Min, max) statistics and change from baseline on day 7.

As a result: on day 1 or day 7 according to BH 4T_maxNo sepiapterin was detected in CSF for +/-30 minutes. The CSF concentration of BH4 increased by 4.102 ng/mL in subjects treated with sepiapterin, but not changed in subjects receiving placebo (change from baseline-0.010 ng/mL). Similarly, the CSF concentration of BH2 increased by 1.368 ng/mL in subjects treated with sepiapterin, but there was no change (-0.020 ng/mL from baseline) in subjects receiving placebo.

The change in neurotransmitter concentration relative to day 1 also varied between subjects treated with sepiapterin and subjects receiving placebo. The concentration of HVA in the subject treated with sepiapterin was increased by 1.378 ng/mL, compared to a 0.630 ng/mL decrease in the concentration of HVA in subjects receiving placebo. The concentration of 5-HIAA decreased in both cohorts, but the concentration of 5-HIAA decreased to a lesser extent in subjects treated with sepiapten than in subjects receiving placebo (-1.142 ng/mL vs. -2.440 ng/mL).

Notably, the pre-dose HVA (10.02 ng/mL) and 5-HIAA (3.69 ng/mL) concentrations on day 1 of one subject were approximately one-third of those observed in the other subjects (HVA: 22.45 to 44.72 ng/mL; 5-HIAA: 9.49 to 19.70 ng/mL). However, on day 7, the HVA (29.93 ng/mL) and 5-HIAA (9.53 ng/mL) concentrations of this subject approached the ranges observed in other subjects administered sepiaptin (HVA: 30.64 ng/mL to 43.19 ng/mL; 5-HIAA: 10.10 ng/mL to 21.59 ng/mL). The HVA and 5-HIAA concentrations in this subject on day 7 were higher than the mean concentration in placebo-treated subjects on day 7. The data are summarized in table 6 below.

Table 6. concentration of analyte in CSF of subject.

Example 4 pharmacokinetic analysis with multiple doses of sepiapterin

The method comprises the following steps: three groups of eight fed subjects were each randomized to receive either sepiaptin or placebo once daily at a ratio of 6:2 for 7 days. A sentinel dosing strategy was also used to administer the highest dose of sepiapterin.

As a result: the plasma-time concentrations of sepiapterin and BH4 were similar after 1 day and 7 days of treatment with sepiapterin, with no drug accumulation. The pharmacokinetic data are shown in table 7 below.

TABLE 7 summary of pharmacokinetic data for multiple administration of sepiapterin

NC is not calculated.

Other embodiments

It is to be understood that while the present disclosure has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the disclosure, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.